Table 1. Characteristics of patients.
| Group | n | m/f | Age, years median (min-max) | Heparin type | Heparin dosage | Point 0/Point 1/Point 2 | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Time* | APTT n |
TD n |
Anti-Xa n |
TGT n |
TEG n |
||||||
| 1 DVT |
24 | 14/10 | 59 (24–86) | LMWH | 6000 IU 2x a day |
Bef/3h/12h | 24/21/23 | 23/21/22 | 24/21/24 | - | - |
| 71 | 46/25 | 57 (21–84) | UFH | 150 IU/kg 3x a day |
Bef/2h/8h | 64/67/64 | 64/58/64 | - | 54/50/50 | - | |
| 29 | 15/14 | 67 (28–87) | UFH | 150 IU/kg 3x a day |
Bef/-/8h | 29/-/25 | 29/-/28 | - | - | - | |
| 2 SURGERY |
42 | 21/21 | 60 (37–76) | LMWH | 4000 IU 1x a day |
Bef/-/24h | 29/-/39 | 13/-/22 | - | 18/-/32 | 27/-/38 |
| 26 | 11/15 | 51 (20–75) | LMWH | 3000 IU 1x a day |
Bef/3h/24h | 26/25/26 | 26/26/26 | 24/26/25 | 10/10/16 | 24/23/22 | |
| 10 | 3/7 | 54 (26–65) | LMWH | 4000 IU 1x a day |
Bef/3h/24h | 5/10/9 | 5/10/9 | 5/10/9 | - | - | |
| 3 ONCO |
34 | 21/13 | 56 (27–65) | UFH | 1200 IU/d | Bef/24h†/NA | 30/27/ NA | 30/27/ NA | - | 27/23/ NA | 29/27/ NA |
| 14 | 4/10 | 43 (23–80) | UFH | 1200 IU/d | Bef/24h†/NA | 14/14/ NA | 14/14/ NA | - | - | 13/12/ NA | |
DVT—patients with lower extremity DVT; SURGERY—early postoperative patients; ONCO—patients with hematological malignancies; APTT—activated partial thromboplastin time; TD—thrombodynamics; TGT—thrombin generation test; TEG—thromboelastography; m/f = male/female; Bef—before administration of heparin; NA—not applicable; n—number of participants.
* Time between heparin injection and blood sampling (at maximal blood heparin concentration).
† 24h after continuous heparin infusion.